GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GeoVax Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$0.23−0.01 (-4.53%)
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
GeoVax Labs, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NIH Grants [Member] | $385.50K | $472.16K | $673.08K | $894.86K | $1.44M | $1.42M | $1.40M | $1.28M | $983.68K | $1.04M | $1.16M | $1.07M | 100.0% | -73.2% |
| Research Agreements [Member] | – | – | – | – | $385.19K | $424.05K | $358.36K | $244.26K | $192.21K | $168.36K | $58.54K | $38.54K | – | – |
By region
From the segment and revenue-disaggregation notes of GeoVax Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.